Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial
Daniel P Petrylak, Nicholas J Vogelzang, Nikolay Budnik, Pawel Jan Wiechno, Cora N Sternberg, Kevin Doner, Joaquim Bellmunt, John M Burke, Maria Ochoa de Olza, Ananya Choudhury, Juergen E Gschwend, Evgeny Kopyltsov, Aude Flechon, Nicolas Van As, Nadine Houede, Debora Barton, Abderrahim Fandi, Ulf Jungnelius, Shaoyi Li, Ronald de WitKarim Fizazi
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial'. Together they form a unique fingerprint.